Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
McKesson
Mallinckrodt
Express Scripts
Boehringer Ingelheim

Last Updated: May 24, 2022

CLINICAL TRIALS PROFILE FOR DAKLINZA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Daklinza

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02565862 ↗ A Drug-drug Interaction Study Between Daclatasvir and Metformin Completed Radboud University Phase 1 2016-01-01 This study aims to provide clinical information on a potential drug-drug interaction between daclatasvir and metformin.
NCT02565888 ↗ A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat Completed Radboud University Phase 1 2015-11-01 This study aims to provide the evidence that 150mg of cobicistat will have the same effect on the pharmacokinetics of daclatasvir 30mg QD as 100mg of ritonavir, when given together with atazanavir 300mg.
NCT02640157 ↗ A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection Completed AbbVie Phase 3 2015-12-01 The purpose of this study was to compare the safety and efficacy of ABT-493/ABT-530 to the combination of sofosbuvir (SOF) and daclatasvir (DCV) in adults with genotype 3 (GT3) chronic hepatitis C virus (HCV) infection.
NCT02675127 ↗ Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK) Completed European Egyptian Pharmaceutical Industries Phase 1 2015-12-01 An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Pharmaceutical Industries, Egypt) versus Daklinza 60 mg tablets (Bristol-Myers Squibb Pharma, UK) in Healthy Human Volunteers Under Fasting Condition
NCT02675127 ↗ Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK) Completed Genuine Research Center, Egypt Phase 1 2015-12-01 An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Pharmaceutical Industries, Egypt) versus Daklinza 60 mg tablets (Bristol-Myers Squibb Pharma, UK) in Healthy Human Volunteers Under Fasting Condition
NCT02756936 ↗ Bioequivalence Study of Daclatasvir From Daclatasvir Zeta 60 mg Film Coated Tablets (Zeta Pharm Pharmaceutical Industries, Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK) Completed Zeta Pharma Pharmaceutical Industries Phase 1 2016-02-01 An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daclatasvir zeta 60 mg F.C.T ( Zeta Pharm Pharmaceutical Industries, Egypt) versus Clatazev 60 mg F.C.T (Bristol-Myers Squibb Pharma, UK) in Healthy Human Volunteers Under Fasting Condition
NCT02756936 ↗ Bioequivalence Study of Daclatasvir From Daclatasvir Zeta 60 mg Film Coated Tablets (Zeta Pharm Pharmaceutical Industries, Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK) Completed Genuine Research Center, Egypt Phase 1 2016-02-01 An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daclatasvir zeta 60 mg F.C.T ( Zeta Pharm Pharmaceutical Industries, Egypt) versus Clatazev 60 mg F.C.T (Bristol-Myers Squibb Pharma, UK) in Healthy Human Volunteers Under Fasting Condition
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Daklinza

Condition Name

Condition Name for Daklinza
Intervention Trials
Healthy 3
Hepatitis C 3
Chronic Hepatitis C 2
Hepatitis C, Chronic 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Daklinza
Intervention Trials
Hepatitis C 8
Hepatitis 7
Hepatitis C, Chronic 5
Hepatitis A 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Daklinza

Trials by Country

Trials by Country for Daklinza
Location Trials
United States 15
Egypt 4
Netherlands 2
Russian Federation 2
Sweden 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Daklinza
Location Trials
New Mexico 1
Minnesota 1
Louisiana 1
Florida 1
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Daklinza

Clinical Trial Phase

Clinical Trial Phase for Daklinza
Clinical Trial Phase Trials
Phase 3 2
Phase 2/Phase 3 3
Phase 2 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Daklinza
Clinical Trial Phase Trials
Completed 10
Unknown status 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Daklinza

Sponsor Name

Sponsor Name for Daklinza
Sponsor Trials
Genuine Research Center, Egypt 3
Radboud University 2
Tanta University 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Daklinza
Sponsor Trials
Other 13
Industry 9
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Express Scripts
Moodys
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.